FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1322-1324 October 30, 1997 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Treatment of symptomatic neurosyphilis is an increasingly common clinical problem because of its rising incidence, particularly in patients coinfected with the human immunodeficiency virus type 1 (HIV-1).¹ The mainstay of treatment remains intravenous penicillin G at high dosage, ranging from 12 million to 24 million units given six times a day for 10 to 14 days.¹ Treatment options for patients with neurosyphilis who are allergic to penicillin are limited. Such patients should undergo a skin test and hospitalization for a penicillin-desensitization protocol before intravenous penicillin administration.^2,3 We know little, however, about the outcomes of high-dose penicillin G . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Primavera, A., Gazzola, P., De Maria, A. F., Treib, J., Grauer, M. T., Woessner, R., Haass, A. (1999). Neuropsychological deficits in neuroborreliosis. Neurology 53: 895-895 [Full Text]